

DAFTAR PUSTAKA

1. Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Machado LFA, et al. Origin, Transmission, Diagnosis and Management of Coronavirus Disease 2019 (COVID-19). *Postgrad Med J.* 2020;96:753-8.
2. Yuce M, Filiztekin E, Ozkaya KG. COVID-19 Diagnosis – A Review of Current Methods. *Biosensors and Bioelectronics.*2021.
3. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses.* 2020;12 (372):1-17.
4. Ramadhan P.2020."Diagnosis COVID-19". Fakultas Kedokteran. Universitas Sriwijaya. Palembang.
5. Susilo A, Rumende CM, Pitoyo CW,Santoso WD, Yulianti M,Herikurniawan, dkk. Coronavirus Disease 2019 : Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia.*2020;7(1):45-67.
6. World Health Organization. Coronavirus Disease (COVID-19) Pandemic.2021[updated 2021 March 6th; cited 2021 March 6th
7. Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) Juli 2020. Jakarta : Kementerian Kesehatan Republik Indonesia; 2020.
8. World Health Organization. Coronavirus Disease (COVID-19) Pandemic Update on Coronavirus Disease in Indonesia. 2021 [updated 2021 March 4th; cited 2021 March 6th
9. Fatoni AZ, Rakhmatullah R. Acute Respiratory Distress Syndrome (ARDS) pada Pneumonia COVID-19. *Journal of Anaesthesia and Pain.*2021;2(1):11-24.
10. Khoussaji M, Chapelle V, Evenepoel A, Belkhir L, Yombi JC, Dievoet MAV, et al. A biological profile for diagnosis and outcome of COVID-19 patient. *Clinical Chemistry and Laboratory Medicine.* 2020;58(12):2141-50
11. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. Abnormalities of Peripheral Blood System in Patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta*507. 2020:174-80.
12. Usulan Panduan Pemeriksaan Laboratorium COVID-19. Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia. 2020.

13. Jin A, Yan B, Feng D, Xu B, Liang L, Guo C. Clinical Characteristics of Patients Diagnosed with COVID-19 in Beijing. *Biosafety and Health*. 2020.
14. Circullo A, Borghetti A, Verne LZD, Tosoni A, Lombardi F, Garcovich M, et al. Neutrophil-to-Lymphocyte Ratio and Clinical Outcome in COVID-19: A Report from the Italian Front Line. *International Journal of Antimicrobial Agents*. 2020;18(56):1-3.
15. Jimeno S, Ventura PS, Castellano J M, García-Adasme S I, Miranda M, Touza P. Prognostic implications of neutrophil-lymphocyte Ratio in COVID-19. *Eur. J. Clin. Invest.* 2021;51:e13404
16. Liu Y, Du X, Chen J. Neutrophil-to-lymphocyte Ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect.* 2020;81(1):e6-12.
17. Liu J, Li H, Luo M, Liu J, Wu L, Lin X, et al. Lymphopenia Predicted Illness Severity and Recovery in Patients with COVID-19 : A Single-center, Retrospective Study. *PLOS ONE*. Published On November 18, 2020.
18. Selanoo Y, Widaningsih Y, Esa T, Arif M. Analysis of Neutrophil Lymphocyte Ratio and Absolute Lymphocyte Count as Predictors of Severity of COVID-19 Patient. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2021;27(2):184-9
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395:498-504
20. Handayani D, Hadi DR, Isbaniah F, Burhan E, Agustin H. Penyakit Virus Corona 2019. *Jurnal Respirologi Indonesia*. 2020;40(2):119-29.
21. Azer SA. COVID-19 : Pathophysiology, Diagnosis, Complication, Investigational Therapy. *Department of Medical Education*. 2020;1-8
22. Brenneis R. COVID-19 : Pathophysiology and Clinical Findings.
23. [Casella M](#), [Rajnik M](#), [Cuomo A](#), [Dulebohn S C](#), [Napoli R D](#). Features, Evaluation, and Treatment of Coronavirus (COVID-19). *StatPearls Publishing*. 2021
24. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeftang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database of Systematic Reviews*. 2020
25. Wiersinga JW, Rhodes A, Cheng AC, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020;324(8):782-93.
26. Grace G. Manifestasi Klinis dan Perjalanan Penyakit pada Pasien Covid-19. *Majority*. 2020; 9(1):51-2.

27. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Apr 07;323(13):1239-42.
28. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Geneva: World Health Organization; 2020.
29. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New Engl J Med*. 2020;1708-19.
30. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect*. 2020;1-6.
31. Büyükkaya E, Karakaş M, Karakaş E, Akçay A, Tanboğa I, Kurt M. Correlation of neutrophil to lymphocyte Ratio with the presence and severity of metabolic syndrome. *Clin Appl Thromb Hemost* 2014;20;159- 63.
32. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020;46(5):846-8.
33. Amanda A D. Rasio Neutrofil-Limfosit pada Covid-19; Sebuah Tinjauan Literatur. *Wellness and Healthy Magazine*. 2020;2(2);219-23.
34. Lagunas-Rangel, F. A. Neutrophil-to-lymphocyte Ratio and lymphocyte-to-C-reactive protein Ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *Journal of medical virology*. 2020;1-2.
35. Imran M M, Ahmad U, Usman U, Ali M, Shaukat A, Gul N. Neutrophil/lymphocyte Ratio-A marker of COVID-10 pneumonia severity. *Int J Clin Pract*. 2021;1-7.
36. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol*. 2017;39(5):529–39
37. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-Reactive Protein, Procalcitonin, D-Dimer, and Ferritin in Severe Coronavirus Disease-2019: A Meta-Analysis. *SAGE Journals*.2020;1-14
38. Magro G. SARS-CoV-2 and COVID-19: Is Interleukin-6 (IL-6) the ‘Culprit Lesion’ of ARDS Onset? What is there besides Tocilizumab?SGP13-Fc. *Cytokine*:X.2020.
39. Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A, Zumla A, et al. Immune respon during COVID infection. *Oncoimmunology*.2020;9(1): 23p

40. Letter to the Editor. Lymphopenia during the COVID-19 Infection : What it shows and what can be learned. *Immunology Letters*.2020; 225: 31-32.
41. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-4.
42. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. *Crit Care Resusc*. 2020;22(2):95-7.
43. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. *N Engl J Med*. 2020;382(25):e102
44. Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients with COVID-19. *Am J Emerg Med*. 2021;46:16-9.
45. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. *Blood* 2007;109: 3812–9.
46. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. *Signal. Transduct Target Ther*. 2020; 5: 33.
47. Bermejo-Martin JF, Almansa R, Menéndez R, Mendez R, Kelvin DJ, Torres A. Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. *J Infect*. 2020;80: e23–4.
48. Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting mortality of COVID-19 patients: A systematic review and meta-analysis. *PLoS ONE*. 2020;15(11): e0243124.
49. Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. *Cancers (Basel)*. 2021;13(3):471.
50. Wagner J, DuPont A, Larson S, Cash B, Farooq A. Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review. *Int J Lab Hematol*. 2020;42(6):761-5
51. Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. *Emerg Infect Dis*. 2020;26(8):1839–41.
52. Wang S, Fu L, Huang K, Han J, Zhang R, Fu Z. Neutrophil-to-lymphocyte Ratio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019. *J Infect*. 2021;82(2):e16-8.

53. Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *J. Leukoc. Biol.* 2020;108(1):17–41
54. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* 2020;55(5):1-56
55. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C. Neutrophil-to-lymphocyte Ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. *Journal of Translational Medicine.* 2020;18(1):206-18.
56. Jain V, Yuan JM. Predictive Symptoms and Comorbidities for Severe COVID-19 and Intensive Care Unit Admission: A Systematic Review and Meta-analysis. *International Journal of Public Health.* 2020.
57. Edis E C. Chronic Pulmonary Diseases and COVID-19 . *Turk Thorac J* 2020; 21(5): 345-9
58. Clerkin K J, Fried J A, Raikhelkar J, Sayer G, Griffin J M, Masoumi A, et al. COVID-19 and Cardiovascular Disease. *Circulation.* 2020;141:1648–55.
59. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi B, Rad E M. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. *The Egyptian Heart Journal.* 2020;72(41):1-17
60. Ruocco G. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. *International Journal of Infectious Diseases.* 2020;373–5.
61. Schiffrin E L, Flack J M, Ito S, Muntner P, Webb R C. Hypertension and COVID-19. *American Journal of Hypertension.* 2020: 33(5);373.
62. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and Comorbidities: Deleterious Impact on Infected Patients. *Journal of Infection and Public Health.* 2020:1833-9
63. Hassanein M, Radhakrishnan Y, Vachharajani T, Vachharajani VT, Augustine J, Demirjian S, et al. COVID-10 and the Kidney. *Cleveland Clinic Journal of Medicine.* 2020;87(10):619-31
64. Wu J, Song S, Cao HC, Li LJ. Liver Disease in COVID-19: Etiology, Treatment and Prognosis. *World Journal of Gastroenterology.* 2020;26(19):2286-93

65. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, San K. COVID-19 and Cancer: from Basic Mechanisms to Vaccine Development Using Nanotechnology. *International Immunopharmacology*.2021.
66. Moujaess E, Kourie HR, Ghosn M. Cancer Patients and Research during COVID-19 Pandemic: A Systematic Review of Current Evidence. *Critical Reviews in Oncology/Hematology*.2020.
67. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, *et al.* Pedoman Tatalaksana COVID-19. Third. Jakarta. 2020
68. World Health Organization. Criteria for Releasing COVID-19 Patient from Isolation. 2020.
69. Burhan E. Tatalaksana klinis COVID-19. Satgas Waspada dan Siaga COVID-19 PB IDI.2020
70. Suendra H, Elyazar I, Djaafara B, Ekawati L, Saraswati K, Adrian V, Oktavia D. Clinical characteristics and mortality associated with COVID-19 in Jakarta: a hospital based retrospective cohort study. *The Lancet Regional Health*.2021;9:100-8.
71. Rashedi J, Poor BM, Asgharzadeh V, Pourostadi M, Kafli HS, Vegarl A, Khosroshahl, *et al.* Risk Factors for COVID-19. *Le Infezioni in Medicina*.2020;4 :469-74
72. Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, *et al.* The Value of Clinical Parameters in Predicting the Severity of COVID-19. 2020: 1-17.
73. Grasseli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, *et al.* Risk Factors Associated with Mortality Among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Internal Medicine*. Published Online July 15.
74. Wang JB, Wang HT, Wang LS, Li LP, Xu J, Xu C, *et al.* Epidemiological and Clinical Characteristics of Fifty-six Cases of COVID-19 in Liaoning Province, China. *World Journal of Clinical Cases*. 2020;8(21):5188-202
75. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, *et al.* Factors Associated with Prolonged Viral RNA Shedding in Patients with COVID-19.2020:1-24
76. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, Wright O, *et al.* Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. *PLoS ONE*. 2021; 16(3): 1-12
77. Cheng B, Hu J, Zuo X, Yang G, Shi X, Deng A. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. *Clinical Microbiology and Infection*. 2020; 26 (10); 1400-05

78. Zhang J, Wang M, Zhao M, Guo S, Xu Y, Ding W, et al. The Clinical Characteristics and Prognosis Factors of Mild-Moderate Patients With COVID-19 in a Mobile Cabin Hospital: A Retrospective, Single-Center Study. *Frontiers in Public Health*. 2020; 8; 1-11
79. Ruiz SJ, Ventura PS, Vazquez JMC, Adasme SIG, Garcia MM, Pol PT, et al. Prognostic Implications of Neutrophil-Lymphocyte Ratio in COVID-19. *Wiley*.2020:1-9
80. Gao YD, Ding M, Dong X, Zhang JJ, Azkur AK, Azkur D, et al. Risk Factors for Severe and Critically Ill COVID-19 Patients:
81. Zhu L, She ZG, Cheng X, Guo J, Zhang BH, Li H. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metabolism*. 2020; 31: 1068-77
82. Guo T, Fan Y, Chen M, Wu X, ZHANG L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*. 2020: 1-8.
83. Mohamed NE, Benn EKT, Astha V, Okhawere KE, Korn TG, Nkemdirim W, et al. Association between chronic kidney disease and COVID-19-related mortality in New York. *World Journal of Urology*. 2021;1-7
84. Gibertoni D, Reno C, Rucci P, Fantini MP, Buscaroli, Mosconi G, et al. COVID-19 incidence and mortality in non-dialysis chronic kidney disease patients. *PLOS ONE*. 2021;1-11
85. Ozturk S, Ozturk S, Turgutalp K, Arici M, Odabas AR, Altiparmak MR, Aydin Z. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. *Nephrol Dial Transplant*. 2020;35:2083-95
86. Fillmore NR, La J, Szalat RE, tuck DP, Nguyen V, Yildirim C, et al. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. *JNCI J Natl Cancer Inst*. 2021; 11(6): 691-2
87. Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. *Cancer Biol Med*. 2021;18(1): 298-307
88. Kong X, Qi Y, Huang J, Zhao Y, Zhan Y, Qin X, et al. Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data. *Cancer Letters*. 2021; 30–46

89. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. [Cancer Biol Med](#). 2020; 17(3): 519–27.
90. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Disease are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. *Aging and Disease*. 2020; 11(3): 668-78
91. Sharma A, Jaiswal P, Kerakhan Y, Saravanan L, Murtaza Z, Zargham A, et al. Liver disease and outcomes among COVID-19 hospitalized patients – A systematic review and meta-analysis. *Annals of Hepatology*. 2021;1-8
92. Lin J, Bao B, Khurram N A, Halsey K, Choi J W, Wang L, et al. Chronic liver disease not a significant comorbid condition for COVID-19. *Scientific Reports*. 2021;11;1-6
93. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA*. Published Online April 2020. DOI : 10.1001/jama.2020.6775
94. Biamonte F, Botta C, Mazzitelli M, Rotundo S, Trecarichi EM, Foti D, et al. Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. *Journal of Translational Medicine*. 2021; 19(79); 1-10
95. Terpos E, Stathopoulos LN, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological Findings and Complications of COVID-19. *Am J Hematol*. 2020; 1-14.
96. Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. *Clinical and Applied Thrombosis/Hemostasis*. 2020; 20; 1-7
97. Du P, Li D, Wang A, Shen S, Ma Z, Li X. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2021;1-21
98. Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLOS ONE*. 2021;1-21
99. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical Characteristics of 113 Deceased Patients with Coronavirus disease 2019: Retrospective Study. *BMJ*. 2020;368: m1091: 1-14
100. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology* 2021;64:36–47

Rudiansyah M, Nur'amin HW, Lubis L, Bandiara R, Roesli RMA, Rachmadi D. COVID-19 and Kideny Disease in Indonesia. *Sys Rev Pharm* 2020;11(7):435-42

